Madrigal Pharmaceuticals(MDGL)

Focus: Madrigal is a public small-molecule pharmaceutical company focused on liver and metabolic diseases, with one FDA-approved product (Rezdiffra) and an expanding pipeline in NASH and related indications.

Neurology

Profile data last refreshed 2h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

51+2 this month

Stable — net +2 jobs in 30d

24 added, 22 removed. Backfill posture.

Should You Work at Madrigal Pharmaceuticals?

AI assessment

Strong opportunity for early-career professionals in commercial or regulatory roles seeking launch-phase experience, but limited job security if cash runway or Rezdiffra adoption disappoints.

Why Work Here

One approved product (Rezdiffra/resmetirom) with 20-year LOE providing long-term stability and growth runway in high-demand NASH market.

Data completeness

7/9 — Strong

Company HealthStrong

Pipeline

Late-stage

4 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$0K

Key Products

Rezdiffra

Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis

Growth

Help build intelligence for Madrigal Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

Rezdiffra

MASH - Metabolic Dysfunction-Associated Steatohepatitis

N/A

Clinical Trials (1)

NCT07541469Rezdiffra Pregnancy and Lactation Registry

N/A

MGL-3196

Hepatic Impairment

PHASE_1

Clinical Trials (1)

NCT04643795Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects

Phase 1

MGL-3196

Healthy

PHASE_1

Clinical Trials (1)

NCT04671069Drug Interaction Study of MGL-3196 With Clopidogrel

Phase 1

MGL-3196 Tablet

Healthy

PHASE_1

Clinical Trials (1)

NCT03413124Bioavailability Study of MGL-3196 Tablets Compared to Capsules

Phase 1

Placebo

Drug Safety

PHASE_1

Clinical Trials (1)

NCT01519531Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects

Phase 1

MGL-3196

Healthy

PHASE_1

Clinical Trials (1)

NCT03220165Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196

Phase 1

MGL-3196

Healthy

PHASE_1

Clinical Trials (1)

NCT04671056Drug Interaction Study of MGL-3196 With Pioglitazone

Phase 1

100 mg Resmetirom Tablet

Renal Impairment

PHASE_1

Clinical Trials (1)

NCT06397872A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

Phase 1

Atorvastatin

Healthy

PHASE_1

Clinical Trials (1)

NCT02749578Drug Interaction Study of MGL-3196 With Atorvastatin

Phase 1

Simvastatin

Healthy

PHASE_1

Clinical Trials (1)

NCT02542969Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin

Phase 1

Placebo

Drug Safety

PHASE_1

Clinical Trials (1)

NCT01367873Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects

Phase 1

MGL-3196

Non-alcoholic Steatohepatitis

PHASE_2

Clinical Trials (1)

NCT02912260Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Phase 2

MGL-3196

Heterozygous Familial Hypercholesterolemia

PHASE_2

Clinical Trials (1)

NCT03038022Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Phase 2

Resmetirom

MASH - Metabolic Dysfunction-Associated Steatohepatitis

PHASE_2

Clinical Trials (1)

NCT07335601Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

Phase 2

Resmetirom

Non-Alcoholic Fatty Liver Disease

PHASE_3

Clinical Trials (1)

NCT04951219A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Phase 3

Resmetirom

NASH

PHASE_3

Clinical Trials (1)

NCT05500222A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

Phase 3

MGL-3196

NASH - Nonalcoholic Steatohepatitis

PHASE_3

Clinical Trials (1)

NCT03900429A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

Phase 3

Placebo

Non-Alcoholic Fatty Liver Disease

PHASE_3

Clinical Trials (1)

NCT04197479A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients

Phase 3

Interview Prep Quick Facts

Portfolio: 1 approved product, 18 clinical trials

Top TAs: Infectious Diseases, Metabolic Diseases, Gastroenterology

Publications: 25 in PubMed

SEC Filings: 2 available

Open Roles: 51 active jobs

Portfolio Health

Growth1 (100%)

1 total products

Therapeutic Area Focus

1 marketed5 pipeline

1 marketed3 pipeline

2 pipeline

1 marketed

Financials (FY2025)

Revenue

R&D Spend

$272M11%

Net Income

-$374M

Cash

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Self-Reported Cognitive Function in Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Post-hoc Analysis of the MAESTRO Resmetirom Trials.

Journal of clinical and experimental hepatology

2026

PMID:41953252

Burden of metabolic dysfunction-associated steatohepatitis, with and without metabolic syndrome, obesity, or diabetes.

Madrigal Pharmaceuticals(MDGL)

Should You Work at Madrigal Pharmaceuticals?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (1)

Pipeline & Clinical Trials

Recent News · Madrigal Pharmaceuticals(2)

Open Jobs (51)

Director, Marketing Operations

Area Business Manager - Central Alabama

Grants Manager

Quality Assurance Lead - FvP

Associate Director, Pharmacovigilance (PV) Commercial Liaison, Global Clinical Safety and Pharmacovigilance

Quality Compliance Lead International

Director, Medical Society Relations and Alliance Development

Associate Director, Global Aggregate Reporting & Risk Management Plans

Sr. Manager, Marketing & Commercial Excellence

Sr. Director of Strategic Sourcing & Procurement (G&A Categories)

Area Business Manager- Cherry Hill, NJ

Associate Director, Biostatistician

Snr. / Medical Science Liaison UK, London or North England

Senior Biostatistician

Senior Manager International Regulatory Affairs

Associate Director, Commercial Ops and Analytics

Senior Manager Consumer Marketing

Senior Director, Technical Accounting & SEC Reporting

Executive Administrative Assistant

Executive Director, Pricing Strategy, Analytics & Contracting

Senior Director, Access & Reimbursement

Access Reimbursement Manager- San Francisco

Director, Security Architecture and Engineering

Senior Manager, Regulatory Operations Systems Veeva RIM Product Owner

Director, Global Publications Lead

Financials (FY2025)

Hiring Trend

Research Publications(10)